|
The role of 18F-FDG PET/CT-derived metabolic parameters in the early evaluation and prognostic assessment of diffuse large B-cell lymphoma
|
X. Dong   , W. Ge , S. Li , N. Feng |
| Department of Radiology, Affiliated Hospital of Hebei University, Baoding, Hebei, China , hbmufengna@163.com |
|
|
Abstract: (342 Views) |
Background: To investigate the dynamic changes in 18F-FDG PET/CT (18F)-derived metabolic parameters throughout the entire chemotherapy process for diffuse large B-cell lymphoma (DLBCL), and to analyze their clinical value in early diagnosis, curative effect evaluation, and prognosis stratification. Materials and Methods: One hundred and sixty-five patients with suspected DLBCL admitted from April 2022 to May 2023 were included. 18F scans were performed before chemotherapy (baseline), after 3-4 courses of chemotherapy (interim), and 6-8 weeks following chemotherapy completion (post-therapy). SUVmax, SUVmean, and TLG were calculated by delineating the metabolic tumor volume (MTV). Therapeutic efficacy was evaluated using the Deauville 5-point scale. Patients were followed up for 2 years to record their survival outcomes. A combined diagnostic model was constructed using Logistic regression, with its predictive efficiency analyzed using ROC curves. Results: Baseline SUVmax, SUVmean, MTV, and TLG were higher in DLBCL patients than in non-DLBCL cases (P<0.05). The combined model demonstrated an AUC of 0.972, with 93.15% sensitivity and 89.13% specificity. The interim metabolic parameters were highly correlated with Deauville scores. Higher SUVmax, MTV, and TLG levels were observed in the poor-efficacy group than in the good-efficacy group (P<0.05). Besides, the death group exhibited SUVmax, MTV, and TLG elevations compared to the survival group (P<0.05). The area under the ROC curve for the combined detection in predicting the prognostic mortality of DLBCL patients was 0.942 (P<0.001). Conclusion: The temporal variations of metabolic parameters derived from 18F prove valuable for the early detection, therapeutic effect assessment, and prognostic prediction of DLBCL. |
|
| Keywords: 18-F-FDG PET/CT, diffuse large b-cell lymphoma, metabolic parameters, prognosis. |
|
|
Full-Text [PDF 1119 kb]
(68 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. 1. Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Jon EA (2022) Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma, 63(1): 54-63. [ DOI:10.1080/10428194.2021.1975188] 2. Barraclough A and Hawkes EA (2023) Antibody and immunotherapy in diffuse large B-cell lymphoma. Semin Hematol, 60(5): 338-45. [ DOI:10.1053/j.seminhematol.2023.11.001] 3. Bock AM and Epperla N (2025) Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. Journal of Hematology & Oncology, 18(1): 68. [ DOI:10.1186/s13045-025-01702-5] 4. Morin RD, Arthur SE, Hodson DJ (2022) Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol, 196(4): 814-29. [ DOI:10.1111/bjh.17811] 5. Zanoni L, Bezzi D, Nanni C, Paccagnella A, Farina A, Broccoli A, et al. (2023) PET/CT in non-hodgkin lymphoma: An update. Semin Nucl Med, 53(3): 320-51. [ DOI:10.1053/j.semnuclmed.2022.11.001] 6. Sun XY, Chen TX, Chang C, Teng HH, Xie C, Ruan MM, et al. (2021) SUVmax of (18)FDG PET/CT predicts histological grade of lung adenocarcinoma. Acad Radiol, 28(1): 49-57. [ DOI:10.1016/j.acra.2020.01.030] 7. Iwasa H, Nagamachi S, Nakayama S, Yamamoto T, Yoshimitsu K (2023) The reproducibility of MTV and TLG of soft tissue tumors calculated by FDG-PET: Comparison between the lower limit by the fixed value SUV 2.5 and that value by 30% of SUVmax. Jpn J Radiol, 41(5): 531-40. [ DOI:10.1007/s11604-022-01378-8] 8. Li M, Lu H, Fan J, Dai M, Su C (2023) A nomogram prognostic model for diffuse large B-cell lymphoma based on SUVmax and GNRI in elderly patients. EJ Haem, 4(4): 1030-41. [ DOI:10.1002/jha2.794] 9. Lang R and Gill MJ (2021) diffuse large b-cell lymphoma. N Engl J Med, 384(23): 2261-2. [ DOI:10.1056/NEJMc2105452] 10. Ng DZ, Lee CY, Lam WW, Tong AK, Tan SH, Khoo LP, et al. (2022) Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the DeltaSUVmax method. Leuk Lymphoma, 63(1): 256-9. [ DOI:10.1080/10428194.2021.1992624] 11. Miura K, Takahashi H, Nishimaki-Watanabe H, Hamada T, Uchiike A, Tsutsumi D, et al. (2025) Contemporary management of diffuse large B-cell lymphoma in Japan. Expert review of Anticancer Therapy, 25(5): 551-9. [ DOI:10.1080/14737140.2025.2490283] 12. Usmani S, Jain A, Riyami KA, Ahmed N, Al-Sukaiti R, Shamim MS (2024) The role of 18F in neurolymphomatosis: A comprehensive imaging approach. J Pak Med Assoc, 74(4): 822-4. [ DOI:10.47391/JPMA.24-30] 13. Dondolin R, Garrou F, Almasri M, Terzi Di Bergamo L, Cosentino C, Bruscaggin A, et al. (2025) Integration of [(18)F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma. Leukemia, 39(9): 2207-14. [ DOI:10.1038/s41375-025-02688-2] 14. Zhao P, Yu T, Pan Z (2021) Prognostic value of the baseline 18F metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Ann Nucl Med, 35(1): 24-30. [ DOI:10.1007/s12149-020-01531-1] 15. Jin A, Lin X, Yin X, Cui Y, Ma L (2022) Prognostic value of MTV and TLG of 18 F-FDG PET in patients with head and neck squamous cell carcinoma: A meta-analysis. Medicine (Baltimore), 101(39): e30798. [ DOI:10.1097/MD.0000000000030798] 16. Xie W, Cao L, Yu J, Tian A, Wang J, Lin R (2025) (18)F-FDG PET/CT metabolic parameter changes to assess vascular inflammatory response in patients with diffuse large B-cell lymphoma. BMC Med Imaging, 25(1): 81. [ DOI:10.1186/s12880-025-02078-1] 17. Wen W, Piao Y, Xu D, Li X (2021) Prognostic value of MTV and TLG of (18)F-FDG PET in patients with stage I and II non-small-cell lung cancer: a Meta-Analysis. Contrast Media Mol Imaging, 2021: 7528971. [ DOI:10.1155/2021/7528971] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Dong X, Ge W, Li S, Feng N. The role of 18F-FDG PET/CT-derived metabolic parameters in the early evaluation and prognostic assessment of diffuse large B-cell lymphoma. Int J Radiat Res 2026; 24 (3) :729-734 URL: http://ijrr.com/article-1-7230-en.html
|
